SCHEMBL8224976

SCHEMBL8224976

COC1COC2C(OC(C)=O)COC12

nearest known ligand 0.49

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
BCHE P06276 11/20 0.49
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.37
PDE1C Q14123 1/20 0.36
CHRM2 P08172 2/20 0.35
MEN1 O00255 1/20 0.35
CYP2D6 P10635 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL822719 1.00 BCHE (0.49) BCHEALDH1A1MAPTPDE1CCHRM2
SCHEMBL26205730 1.00 BCHE (0.49) BCHEALDH1A1MAPTPDE1CCHRM2
SCHEMBL822521 1.00 BCHE (0.49) BCHEALDH1A1MAPTPDE1CCHRM2
SCHEMBL822750 1.00 BCHE (0.49) BCHEALDH1A1MAPTPDE1CCHRM2
SCHEMBL16261717 1.00 BCHE (0.49) BCHEALDH1A1MAPTPDE1CCHRM2
SCHEMBL822629 1.00 BCHE (0.49) BCHEALDH1A1MAPTPDE1CCHRM2
SCHEMBL12199932 0.92 BCHE (0.54) BCHEALDH1A1MAPTCHRM2MEN1
SCHEMBL7150802 0.92 BCHE (0.54) BCHEALDH1A1MAPTCHRM2MEN1
SCHEMBL7152562 0.92 BCHE (0.54) BCHEALDH1A1MAPTCHRM2MEN1
SCHEMBL7276665 0.92 BCHE (0.54) BCHEALDH1A1MAPTCHRM2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 WO disclosed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 EP disclosed
US-20240239962-A1 POLYCARBONATE RESIN COMPOSITION AND MOLDED ARTICLE IDEMITSU KOSAN CO.,LTD. (JP) 2024-07-18 US disclosed
US-20230167235-A1 Polyester Carbonates Having a Defined Proportion of Ester Groups COVESTRO DEUTSCHLAND AG (DE) 2023-06-01 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed
US-20230145772-A1 Polyester Carbonates Consisting of Different Diols in a Defined Ratio COVESTRO DEUTSCHLAND AG (DE) 2023-05-11 US disclosed
US-20230052441-A1 POLYCARBONATE/POLYORGANOSILOXANE COPOLYMER AND RESIN COMPOSITION INCLUDING SAID COPOLYMER IDEMITSU KOSAN CO.,LTD. (JP) 2023-02-16 US disclosed
US-20230046996-A1 POLYCARBONATE/POLYORGANOSILOXANE COPOLYMER AND RESIN COMPOSITION INCLUDING SAID COPOLYMER IDEMITSU KOSAN CO.,LTD. (JP) 2023-02-16 US disclosed
US-20230038766-A1 POLYCARBONATE/POLYORGANOSILOXANE COPOLYMER AND RESIN COMPOSITION INCLUDING SAID COPOLYMER IDEMITSU KOSAN CO.,LTD. (JP) 2023-02-09 US disclosed
EP-4071195-A1 POLYCARBONATE/POLYORGANOSILOXANE COPOLYMER AND RESIN COMPOSITION INCLUDING SAID COPOLYMER Idemitsu Kosan Co., Ltd (JP) 2022-10-12 EP disclosed
US-8034894-B2 Terminal modified polycarbonate and manufacturing process thereof TEIJIN LIMITED (JP) 2011-10-11 US disclosed
US-8008381-B2 Polycarbonate resin composition TEIJIN LIMITED (JP) 2011-08-30 US disclosed
US-20100196720-A1 POLYCARBONATE RESIN AND OPTICAL FILM USING THE SAME ABB TECHNOLOGY LTD. (CH) 2010-08-05 US disclosed
US-20100184884-A1 FLAME-RETARDANT POLYCARBONATE RESIN COMPOSITION TEIJIN LIMITED (JP) 2010-07-22 US disclosed
US-20100160563-A1 POLYCARBONATE RESIN COMPOSITION TEIJIN LIMITED (JP) 2010-06-24 US disclosed
US-20100105854-A1 TERMINAL MODIFIED POLYCARBONATE AND MANUFACTURING PROCESS THEREOF TEIJIN LIMITED (JP) 2010-04-29 US disclosed
US-20100076130-A1 POLYCARBONATE RESIN COMPOSITION TEIJIN LIMITED (JP) 2010-03-25 US disclosed
US-20100048854-A1 POLYCARBONATE RESIN AND MANUFACTURING PROCESS THEREOF TEIJIN LIMITED (JP) 2010-02-25 US disclosed
US-20100029678-A1 DIURETICS MERCK SHARP & DOHME CORP. 2010-02-04 US disclosed
WO-2008002924-A2 QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2008-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029678-A1 DIURETICS NR3C2, REN, NR3C1 BCHE 2877/4885ALDH1A1 2059/4885MAPT 4222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.